A new Mass General Brigham study highlighted Annalise.ai’s pneumothorax detection solution’s strong diagnostic performance, including across different pneumothorax types and clinical scenarios.
The researchers used Annalise Enterprise CXR Triage Pneumothorax to “analyze” 985 CXRs (435 positive), detecting simple and tension pneumothorax cases with high accuracy:
- Simple pneumothorax – 0.979 AUC (94.3% sensitivity, 92.0% specificity)
- Tension pneumothorax – 0.987 AUC (94.5% sensitivity, 95.3% specificity)
The study also suggests that Annalise Enterprise CXR should maintain this strong performance when used outside of Mass General, as it surpassed standard accuracy benchmarks (>0.95 AUC, >80% sensitivity & specificity) across nearly all of the study’s clinical scenarios (CXR manufacturer, CXR projection type, patient sex/age/positioning).
The clinical benefits of early pneumothorax detection are clear, so studies like this are good news for the growing number of FDA-approved pneumothorax AI vendors who are working on clinical adoption.
However, this study feels like even better news for Annalise.ai, noting that it is one of the few pneumothorax AI vendors that detects both simple and tension pneumothorax, and considering that Annalise Enterprise CXR is capable of detecting 122 other CXR indications (even if it’s currently only FDA-cleared for pneumothorax).